Literature DB >> 21325840

Anti-inflammatory treatment.

Susanna K Fistarol, Peter H Itin.   

Abstract

Inflammatory mucosal disorders are treated conventionally with potent or superpotent topical corticosteroids. For more than 20 years, topical cyclosporine has been used in the management of oral mucous membrane affections. Recently other topically applied calcineurin inhibitors, namely tacrolimus and pimecrolimus, expanded the armamentarium for the treatment of inflammatory mucosal diseases. This chapter places its main emphasis on the efficacy and safety of topical calcineurin inhibitors in the management of different oral and genital conditions, including anogenital lichen sclerosus (LS), oral and genital lichen planus, plasma cell balanitis and vulvitis, mucous membrane pemphigoid and pemphigus vulgaris, all conditions having usually a protracted course, requiring long-lasting treatment. There is current evidence for the effectiveness of both pimecrolimus and tacrolimus in the topical treatment of inflammatory oral mucosal diseases and genital dermatoses, especially oral lichen planus and genital LS.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21325840     DOI: 10.1159/000321051

Source DB:  PubMed          Journal:  Curr Probl Dermatol        ISSN: 1421-5721


  3 in total

1.  Porphyromonas gingivalis Fimbria-Induced Expression of Inflammatory Cytokines and Cyclooxygenase-2 in Mouse Macrophages and Its Inhibition by the Bioactive Compounds Fibronectin and Melatonin.

Authors:  Yukio Murakami; Mamoru Machino; Seiichiro Fujisawa
Journal:  ISRN Dent       Date:  2012-04-01

Review 2.  Diagnosis and treatment of lichen sclerosus: an update.

Authors:  Susanna K Fistarol; Peter H Itin
Journal:  Am J Clin Dermatol       Date:  2013-02       Impact factor: 7.403

3.  Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis.

Authors:  Gangwen Han; Li Bian; Fulun Li; Ana Cotrim; Donna Wang; Jianbo Lu; Yu Deng; Gregory Bird; Anastasia Sowers; James B Mitchell; J Silvio Gutkind; Rui Zhao; David Raben; Peter ten Dijke; Yosef Refaeli; Qinghong Zhang; Xiao-Jing Wang
Journal:  Nat Med       Date:  2013-03-10       Impact factor: 53.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.